CODX — Co-Diagnostics, Inc.

Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $146,000, up from $50,000 in Q1 2025.
• Cost of Revenue: $194,000, leading to a gross loss of approximately $48,000 (compared to a gross profit of $29,000 in the prior year).
• Total Operating Expenses: $9.2 million, up from $8.6 million year-over-year, primarily due to increased R&D spending ($5.9 million vs. $4.9 million).
• Net Loss: $9.1 million or $4.06 per share, compared to a net loss of $7.5 million or $7.05 per share in Q1 2025.
• Adjusted EBITDA: Loss of $8.7 million, compared to a loss of $7.4 million in the prior year.
• Cash and Cash Equivalents: $8.2 million at the end of Q1 2026, down from $11.9 million at the end of 2025.

2. Strategic Updates and Business Highlights

• Clinical Pipeline: Enrollment completed for the upper respiratory multiplex test with over 1,400 patients. An initial FDA submission is planned for Q3 2026, focusing on Flu A, Flu B, and RSV.
• India Strategy: CoSara joint venture has received CDSCO clearance for 15 PCR tests and is set to manufacture the PCR Pro instrument locally, expanding its addressable market to approximately $13 billion.
• Saudi Arabia Expansion: CoMira joint venture is progressing with local manufacturing plans, having secured industrial land allocation. This aligns with Saudi Arabia's Vision 2030 initiative.
• Technological Advancements: Enhancements in connectivity, automation, and AI capabilities are being integrated into the platform to improve operational efficiency.

3. Forward Guidance and Outlook

• The company anticipates filing for FDA clearance in Q3 2026 and expects to commence TB testing commercialization in India by the end of Q3 2026.
• Continued focus on disciplined capital allocation and potential financing alternatives, including equity and strategic partnerships, to support growth and development plans.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: The company continues to experience significant operating losses, which are expected to persist in the near term.
• Revenue Generation: Current revenue levels remain limited, and cost variability impacts gross margins.
• Regulatory Risks: Dependence on successful regulatory submissions for product commercialization poses a risk.
• Market Competition: The competitive landscape in molecular diagnostics, particularly in emerging markets like India, could pose challenges.

5. Notable Q&A Insights

• Scalability: The company is well-positioned to meet initial commercial demand, with plans for local manufacturing in India and Saudi Arabia to enhance efficiency and reduce costs.
• Market Strategy: Emphasis on local manufacturing aims to improve accessibility and affordability of diagnostics in underserved regions, particularly in India.
• Clinical Trials: The upcoming TB clinical trials will be conducted in larger medical centers, with a strategy to bridge the gap to smaller facilities post-clearance.

Overall, Co-Diagnostics is making significant strides in its clinical and commercialization efforts, particularly in India and Saudi Arabia, while facing ongoing financial challenges and regulatory hurdles.